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from understanding molecular mecha-
nisms of IPC to therapeutic applica-
tions. A therapeutic approach to AKI
will probably be multifaceted, targeting
multiple pathways at various times. IPC
is a very powerful phenomenon, speci-
fically because it can trigger multiple
layers of (protective) signaling path-
ways. Therefore, understanding the
interactions between various signaling
pathways and the modulatory role of
miRNAs in IPC will no doubt be
essential.
DISCLOSURE
The author declared no competing interests.
ACKNOWLEDGMENTS
TME-A is supported by a Veterans Affairs
Merit Award and a Norman Coplon grant
from Satellite Healthcare. The author
thanks Pierre Dagher from Indiana
University for review and discussion of the
manuscript.
REFERENCES
1. Bonventre JV. Kidney ischemic
preconditioning. Curr Opin Nephrol Hypertens
2002; 11: 43–48.
2. Joo JD, Kim M, D’Agati VD et al. Ischemic
preconditioning provides both acute and
delayed protection against renal ischemia
and reperfusion injury in mice. J Am Soc
Nephrol 2006; 17: 3115–3123.
3. Park KM, Byun JY, Kramers C et al. Inducible
nitric-oxide synthase is an important
contributor to prolonged protective effects
of ischemic preconditioning in the mouse
kidney. J Biol Chem 2003; 278: 27256–27266.
4. Cho WY, Choi HM, Lee SY et al. The role of
Tregs and CD11c(þ ) macrophages/dendritic
cells in ischemic preconditioning of the
kidney. Kidney Int 2010; 78: 981–992.
5. Kinsey GR, Huang L, Vergis AL et al.
Regulatory T cells contribute to the
protective effect of ischemic preconditioning
in the kidney. Kidney Int 2010; 77: 771–780.
6. Lee HT, Emala CW. Protein kinase C and G(i/o)
proteins are involved in adenosine- and
ischemic preconditioning-mediated renal
protection. J Am Soc Nephrol 2001; 12:
233–240.
7. Park KM, Chen A, Bonventre JV. Prevention of
kidney ischemia/reperfusion-induced functional
injury and JNK, p38, and MAPK kinase
activation by remote ischemic pretreatment.
J Biol Chem 2001; 276: 11870–11876.
8. Mkaddem SB, Werts C, Goujon JM et al. Heat
shock protein gp96 interacts with protein
phosphatase 5 and controls toll-like receptor
2 (TLR2)-mediated activation of extracellular
signal-regulated kinase (ERK) 1/2 in post-
hypoxic kidney cells. J Biol Chem 2009; 284:
12541–12549.
9. Xu X, Kriegel AJ, Liu Y et al. Delayed ischemic
preconditioning contributes to renal
protection by upregulation of miR-21. Kidney
Int 2012; 82: 1167–1175.
10. Bhatt K, Mi QS, Dong Z. microRNAs in
kidneys: biogenesis, regulation, and
pathophysiological roles. Am J Physiol Renal
Physiol 2011; 300: F602–F610.
11. Wei Q, Bhatt K, He HZ et al. Targeted deletion
of Dicer from proximal tubules protects
against renal ischemia-reperfusion injury.
J Am Soc Nephrol 2010; 21: 756–761.
12. Godwin JG, Ge X, Stephan K et al.
Identification of a microRNA signature of
renal ischemia reperfusion injury. Proc Natl
Acad Sci USA 2010; 107: 14339–14344.
see original article on page 1176
Strategies to reverse endothelial
dysfunction in diabetic
nephropathy
Shawn S. Badal1,2 and Farhad R. Danesh1,2,3
Endothelial dysfunction underlies the basic pathophysiology of
microvascular complications of diabetes. Endothelial dysfunction is
associated with impaired nitric oxide (NO) availability. Since NO
production is tightly regulated by endothelial nitric oxide synthase
(eNOS), several therapeutic strategies have been investigated and
proposed to improve eNOS bioavailability in the vasculature. The
findings of Cheng et al. suggest that increased availability of eNOS may
be an effective strategy in restoring endothelial function in patients
with diabetic nephropathy.
Kidney International (2012) 82, 1151–1154. doi:10.1038/ki.2012.306
The critical role of endothelial dysfunc-
tion in micro- and macrovascular com-
plications of diabetes has generated
considerable interest in identifying strate-
gies to improve endothelial function in
the diabetic milieu. An interesting study
by Cheng et al.1 confirms the impor-
tance of endothelial nitric oxide synthase
(eNOS) activity in endothelial dysfunc-
tion, and reports that improving eNOS
activity ameliorates progression of dia-
betic nephropathy. This work provides
evidence for a key role of endothelial
dysfunction in the progression of
diabetic nephropathy, and supports a
rationale for pharmacological targeting
of the eNOS pathway as a novel strategy
in the treatment of diabetic kidney
disease.
The endothelium is not only a
monolayer of endothelial cells that lines
the entire vascular system, but also
exerts significant autocrine, paracrine,
and endocrine actions modulating
vasodilation, smooth muscle cell growth
and migration, and inflammatory res-
ponses. Many of these effects are medi-
ated by nitric oxide (NO). NO opposes
the effects of endothelium-derived vaso-
constrictors such as angiotensin II and
endothelin, protects against endothe-
lial-cell damage induced by cytokines
such as tumor necrosis factor, and
provides antithrombogenic effects by
blocking the release of von Willebrand
factor. Indeed, a defect in the pro-
duction or activity of NO promotes
key features of endothelial dysfunc-
tion, such as vasoconstriction, platelet
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aggregation, smooth muscle cell proli-
feration and migration, leukocyte adhe-
sion, and oxidative stress.
NO is formed in endothelial cells
from its precursor L-arginine (L-arg) via
the enzymatic action of endothelial
NO synthase (eNOS), which is localized
at the plasma membrane caveolae. The
protein caveolin-1 binds to calmodulin
to inhibit the activity of eNOS; the
binding of calcium to calmodulin
displaces caveolin-1, leading to activa-
tion of eNOS and increased production
of NO. Cofactors such as tetrahydro-
biopterin (BH4) and nicotinamide ade-
nine dinucleotide phosphate (NADPH)
are important regulators that contri-
bute to NO production. Optimal
concentrations of BH4 are important
for the normal function of eNOS, and
the depletion of BH4 may result in
‘uncoupling’ of eNOS with a subse-
quent increase in superoxide produc-
tion instead of NO. At the molecular
level, eNOS (a 1203-amino acid,
133-kDa protein encoded by NOS3)
has a bidomain structure and functions
as a dimer. Within each monomer, an
NH2-terminal oxygenase domain binds
a prosthetic heme group, BH4, oxygen,
and the substrate L-arg and supports
the catalytic activity. A peptide
sequence containing a consensus cal-
modulin-binding site links the oxy-
genase domain to a COOH-terminal
reductase domain containing binding
sites for flavin adenine dinucleotide,
flavin mononucleotide, and NADPH.
The active dimeric form of eNOS is
phosphorylated at serine 1179, whereas
phosphorylation at threonine 495
decreases eNOS activity. The molecular
basis of eNOS signaling is shown in
greater detail in Figure 1.
Endothelial dysfunction and decrea-
sed bioavailability of NO have long
been proposed as some of the earliest
signs of diabetic microangiopathy and
major contributors to the progression
of diabetic nephropathy. Indeed, one of
the earliest connections of endothe-
lial dysfunction to the pathogenesis
of diabetic nephropathy was made
nearly 30 years ago when Jensen et al.
described increased plasma concen-
trations of von Willebrand factor and
tissue plasminogen activator, both
markers of endothelial damage, in
patients with diabetic nephropathy.2,3
Since then, various hypotheses have
been put forward to explain the adverse
effects of diabetes on the endothelium.
Some possible targets of dysregulation
leading to impaired bioavailability
of NO in the diabetic milieu include
advanced glycation end products, alter-
ations in the cellular redox state by
an altered NADH/NADþ ratio, dysregu-
lation of protein kinase C, and the
accumulation of sorbitol. Interestingly,
oxidative stress can interfere with the
production and activity of NO by a
number of mechanisms that are inde-
pendent of hyperglycemia. For example,
the free radical superoxide anion rapidly
inactivates NO and destroys BH4,
a cofactor required for NO synthesis.
Even when NO is produced properly, it
can subsequently be rapidly inactivated
by O2
 , particularly under conditions
of high oxidative stress. In addition,
hyperglycemia may influence endo-
thelial homeostasis indirectly through
increased synthesis of growth factors, in
particular transforming growth factor-b
and vascular endothelial growth factor.
Insulin resistance is also believed to
promote endothelial dysfunction. Defi-
ciency of endothelium-derived NO is
believed to be the primary defect link-
ing insulin resistance and endothelial
dysfunction.
The development of eNOS-null
(eNOS–/–) mice was a major advance-
ment in further understanding the
impact of eNOS activity on kidney
function. eNOS–/– mice exhibit an
increase in blood pressure and display
signs of endothelial dysfunction.4 This
evidence served as a strong indicator
of the importance of readily available NO
to maintain normal endothelial function.
A natural extension of these studies was
to investigate the role of eNOS in the
context of diabetes and its major micro-
vascular complications. Importantly,
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Figure 1 | The role of eNOS in endothelial dysfunction. NO is produced by the
action of eNOS on L-arginine. This reaction requires a number of cofactors, including
tetrahydrobiopterin (BH4) and nicotinamide adenine dinucleotide phosphate (NADPH).
Under physiological conditions, eNOS is phosphorylated at Ser1179 and forms homodimers.
However, under conditions associated with endothelial dysfunction, eNOS can be
dephosphorylated and eNOS dimerization can be compromised. Potential therapeutic options
for treating endothelial dysfunction by modulating eNOS activity include administration
of L-arginine or its essential cofactor BH4 or sepiapterin (a BH4 analog).
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mice with diabetes-induced eNOS defi-
ciency exhibited significant worsening
of albuminuria and histological changes
consistent with human diabetic nephro-
pathy, including those typically not seen
in other mouse models of diabetic
nephropathy, such as Kimmelstiel–
Wilson-like nodules and arteriolar hyali-
nosis.5,6 The dramatic histological
changes observed in eNOS–/– mice with
type 1 and type 2 models of diabetes
helped to position eNOS as a critical
factor contributing to the progression of
diabetic kidney disease.
Not surprisingly, pharmacological
activation of the eNOS pathway has
emerged as an attractive approach to
ameliorate endothelial dysfunction and
progression of diabetic nephropathy. In
this regard, a variety of strategies have
been proposed with varying degrees
of success. For instance, statins have
been shown to increase the stability of
eNOS through their pleiotropic effects
by blocking the generation of geranyl-
geranyl pyrophosphate with the subse-
quent inhibition of the Rho–Rho kinase
pathway.7 The role of antioxidants
has also been investigated as possible
therapy for endothelial dysfunction.
Production of oxygen-free radicals
in the vessel wall is thought to quench
eNOS activity, leading to endo-
thelial dysfunction. However, the effec-
tiveness of antioxidants for endo-
thelial dysfunction is not fully esta-
blished,8 and further research is clearly
needed.
Alterations in BH4-dependent eNOS
activity have also been implicated in
diabetic endothelial dysfunction. eNOS
has been shown to generate superoxide
that is critically controlled by BH4
levels.9 This NADPH-dependent form-
ation of superoxide anion by eNOS
occurring at low levels of BH4 has
been referred to as ‘uncoupling’ of NOS
activity, where instead of NO produc-
tion, eNOS generates superoxide anions.
Notably, administration of BH4 or
precursors such as sepiapterin has been
reported to improve endothelial dysfunc-
tion. One interpretation of these findings
is that the increase in oxidative stress that
appears to accompany most, if not all,
disease processes associated with endo-
thelial dysfunction may potentially be a
result of inadequate BH4 concentrations
within the vasculature, with ensuing
uncoupling of eNOS, increased super-
oxide formation, and diminished NO
formation.
The work by Cheng et al.1 (this
issue) provides a fresh look at supple-
mentation with L-arg and sepiapterin
(a BH4 analog) as a potential thera-
peutic strategy for restoring endothelial
function and ameliorating progression
of diabetic nephropathy. The authors
initially examined the effect of L-arg
and sepiapterin supplementation in the
presence of high glucose on glomerular
endothelial cells. They observed a signi-
ficant decrease in permeability and
cellular apoptosis. This was attributed
to an increase in eNOS activity, as seen
by a correction in eNOS dimerization,
serine 1179 phosphorylation, and nitrate/
nitrite synthesis (NO metabolism end
products). The authors then confirmed
their in vitro findings by allocating db/db
mice with advanced diabetic nephro-
pathy (age 26–34 weeks) to either L-arg
or sepiapterin supplementation for
8 weeks. They found a significant reduc-
tion in glomerular basement membrane
thickness and improved albuminuria.
Interestingly, there was no change in
mesangial matrix deposition in treated
versus control animals, implying an
eNOS-independent mechanism involved
in mesangial matrix expansion.
The report by Cheng et al.1 provides
strong evidence on the effectiveness of
therapies targeting impaired eNOS acti-
vity and thereby endothelial dysfunc-
tion in experimental models of diabetic
nephropathy. This study, however, raises
a number of interesting questions. For
instance, would combination therapy
with L-arg and sepiapterin show further
improvement in endothelial dysfunction
and amelioration of progression of dia-
betic nephropathy? Is L-arg or sepiapterin
supplementation beneficial when coupled
with statins or other vasoprotective
modalities commonly used for endo-
thelial dysfunction? And finally, although
these findings are in agreement with a
number of studies reporting on the bene-
ficial effects of chronic BH4 supplemen-
tation on endothelial function, long-term
exposure to BH4 has also been reported
to result in a further derangement of
endothelial function, possibly because
BH4 itself can enter the redox cycle and
generate superoxide.10 Whether these
differences are due to unrecognized
secondary reactions of sepiapterin as
opposed to BH4 itself or due to a
bimodal dose-dependent therapeutic
efficiency of BH4 remains unknown.
Further studies are necessary to establish
the real effectiveness of therapies geared
specifically to target endothelial
dysfunction in patients with diabetic
nephropathy. These findings, if
confirmed in clinical trials, will be
an important advance in developing
new drugs for the treatment of
diabetic nephropathy and will place
restoring eNOS activity and improv-
ing endothelial dysfunction at the
forefront of strategies to prevent and
treat microvascular complications of
diabetes.
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Lixivaptan: a vasopressin receptor
antagonist for the treatment of
hyponatremia
Mitchell H. Rosner1
Hyponatremia, the most common electrolyte disorder encountered in
clinical practice, is associated with significant morbidity and mortality.
The introduction of medications that specifically antagonize the
vasopressin V2 receptor (vaptans) has provided a safe and effective
means of therapy. Lixivaptan is the newest of these agents that reliably
increase serum sodium levels in patients with euvolemic hyponatremia.
However, significant questions remain regarding the specific indications
for vaptans, and their potential impact on morbidity and mortality
associated with hyponatremia.
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Hyponatremia is the most common
electrolyte disorder encountered in clini-
cal practice, and recent data have demon-
strated that it is associated with an
increase in mortality and morbidity even
in patients in whom overt clinical symp-
toms may not be demonstrable.1–3 Typi-
cally, the evaluation of patients with
hyponatremia relies on assessment of
volume status and classifies patients into
hypovolemic, euvolemic, and hyper-
volemic states. This classification schema
allows for determination of the under-
lying cause as well as aiding the clinician
in making decisions on appropriate
therapy. The most common forms of
hyponatremia encountered in clinical
practice are hypervolemic (due to con-
gestive heart failure or cirrhosis) and
euvolemic (largely due to the syndrome
of inappropriate antidiuretic hormone
action). Traditional therapies for hypo-
natremia have been limited, suboptimal,
unreliable, and potentially toxic (Table 1).
However, in 2005 the first drug that
specifically antagonizes arginine vasopres-
sin action at the receptor level was
approved (the intravenous drug conivap-
tan, which antagonizes both the vaso-
pressin V1a and V2 receptors) (Figure 1).
In 2009, an oral vasopressin V2 receptor
antagonist, tolvaptan, was also approved
for the treatment of euvolemic and
hypervolemic hyponatremia. Both of
these agents (broadly termed ‘vaptans’)
had clinical trial data demonstrating their
efficacy in increasing serum sodium levels
as well as increasing the percentage of
patients with hyponatremia who normali-
zed their serum sodium levels as com-
pared with placebo.4,5 Data also demon-
strate the long-term safety and efficacy
(out to approximately 2 years) of
tolvaptan.6 The ability to specifically
target arginine vasopressin provided a
physiologically based therapy for hypo-
natremia that was safe and reliable.
In two articles in this issue of Kidney
International, Abraham and colleagues
report on the effects of a new oral,
non-peptide vasopressin V2 receptor,
lixivaptan, in the treatment of both in-
and outpatients with euvolemic hypo-
natremia.7,8 The studies, LIBRA and
HARMONY, differ in that the former
trial required initial titration of
lixivaptan in the inpatient setting,
whereas, in the latter trial, lixivaptan was
initiated in the outpatient setting (Table 2
summarizes the key characteristics and
outcomes of both trials). Both studies
are randomized, multinational, double-
blinded placebo-controlled phase 3 trials.
In both studies, the dosage of lixivaptan
was titrated on the basis of daily serum
sodium measurements. In both trials,
patients randomized to lixivaptan showed
greater rises in serum sodium values at
day 7 after initiation of therapy, and were
more likely to normalize their serum
sodium, than those given placebo. Cessa-
tion of lixivaptan in both trials led to
worsening of hyponatremia, suggesting
that chronic therapy may be required in
some patients.
Unique to the HARMONY study
was the avoidance of in-hospital drug
initiation and titration, which is cur-
rently recommended with tolvaptan.
Using an outpatient strategy of starting
patients on the lowest possible dose of
lixivaptan (25mg) with point-of-care
testing of the serum sodium at 8 hours
post-dose, the investigators demon-
strated that only three patients in the
lixivaptan group (and one in the placebo
group) exceeded the desired sodium
correction rates in the first 24 h; no sub-
jects experienced an increase in serum
sodium greater than 18mmol/l within
either a 48- or a 72-hour period; and
no subjects had symptoms of osmotic
demyelination syndrome. The ability to
initiate therapy for hyponatremia in the
outpatient setting is advantageous but
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